Goldman Sachs Discloses 6.3% Stake in Karyopharm Therapeutics

The Goldman Sachs Group Inc., through its subsidiary Goldman Sachs & Co. LLC, has disclosed beneficial ownership of 1,429,197.87 shares of Karyopharm Therapeutics Inc. common stock as of June 30, 2026. This represents a 6.3% stake in the company.

The filing with the Securities and Exchange Commission (SEC) indicates that Goldman Sachs & Co. LLC has shared voting and dispositive power over all the reported shares. However, the parent holding company, The Goldman Sachs Group Inc., disclaims beneficial ownership of certain client and fund-related holdings as described in the filing.

The Schedule 13G filing is a formal document that investors file with the government when they acquire a large ownership stake in a company. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions.